
|Articles|July 1, 2003
Tailoring Tx to Disease Stage
San Francisco - When treating cutaneous T-cell lymphoma (CTCL), dermatologists will want to tailor their treatment to the stage of the disease, according to Madeleine Duvic, M.D., who spoke at the annual meeting of the American Academy of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Delgocitinib Advances to Phase 3 Evaluation for Lichen Sclerosus
2
The “6-7” Advances for Dermatologists to Look Forward to in 2026
3
Obagi Launches ALOHA Program to Capture Real-World Insights in Aesthetic Injectables
4
Quoin Targets World’s First Approval for Netherton Syndrome Therapy in Saudi Arabia
5



















